Purple Biotech Presents New Preclinical Data On CAPTN-3 Tri-Specific Antibody Platform At EACR 2025

Author: Benzinga Newsdesk | June 23, 2025 07:06am

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal from June 16-19, 2025.

Key Highlights from the Poster Presentation:

• Robust In Vivo Anti-Tumor Activity: The lead CAPTN-3 tribody, IM1240 (capped-CD3×5T4×NKG2A), induced sustained tumor regression in a triple negative breast cancer (TNBC) xenograft model.
• Conditional, Tumor-Restricted Activation: The ‘capped' CD3 arm remained inactive in serum samples of advanced cancer patients and healthy donors and is selectively unmasked by TME proteases, expanding the therapeutic window and reducing potential systemic NKG2A+NK cell depletion.
• Dual Innate and Adaptive Engagement: IM1240's NKG2A checkpoint blockade arm synergizes with the CD3 engager to activate both innate and adaptive immune subsets, translating to potent cytotoxicity in vitro and in vivo. The poster demonstrates:
  • Activation of the extremely high antitumor NKG2A+ gamma delta 2 T effector cells
  • Reinvigoration of exhausted T cells against solid tumor cells
  • The added value of IM1240 NKG2A arm to the in-vivo tumor suppression
• Plug & Play Flexibility: Additional CAPTN‑3 tribodies, such as IM1060 (CD3×5T4×NKG2D) and IM1065 (CD3×EGFR×NKG2A), demonstrated significant tumor regression, underscoring the platform's modularity and customizable capabilities.
• Superior efficacy versus combination of individual antibodies was demonstrated.

Posted In: PPBT